Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Cantargia, Audiocast with teleconference, Press Conference, 2024

By Inderes11/7/2024, 9:00 AM
Cantargia

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

Yaron
00:01 - 23:27

Thank you so much. It's a pleasure to be here and to present our new suggested financing. And while doing that, I will give you a background on Cantargia and explain why we're undertaking this financing now and what we aim to achieve. So for those of you who don't know Cantargia, we are an IL1RAP antibody company and we have two clinical programs right now, one in cancer and one in autoimmune inflammatory diseases. And we have made good progress in both programs. Nadunolimab. We have treated more than 300 patients with cancer, and we have interesting data to which we will come back. And we also have a randomized phase two trial ongoing in triple-negative breast cancer and in CAN10. We are still in Phase 1, but we are generating a lot of interest from the outside world, since this is really in a very interesting area where the focus for drug development is right now. And we'll come into that one as well. With this rights issue, we will extend our runway and we will come back to that later on as well. I would also like to point out that we have a very good IP on our programs, with the cancer program Nadunolimab having composition of matter patents until 2035. Unless extensions are granted with extended market exclusivity, the corresponding CAN10 patents remain valid until at least 2041. So? So, the pipeline looks like this: Nadunolimab. Uh, we have most of the data in pancreatic cancer, in non-small cell lung cancer, solid phase two data, and the triple negative breast cancer trial is ongoing. In the near future, we also expect to start a fully financed trial in leukemia. In CAN10, the lead indications would be Hidradenitis Suppurativa, which is a quite common dermatological disease, and also a more orphan type of disease like systemic sclerosis. And we're making progress in preparations for Phase 2. And finally, our CAN10 program encompasses a range of new antibodies that can be used either as diagnostics, which is highly relevant to our current activities, but also for novel follow-up concepts like antibody-drug conjugates or bispecific antibodies. So, if we start with the CAN10 program, it focuses on autoimmune inflammatory diseases. CAN10. CAN10 is a unique antibody because it blocks three different disease-promoting cytokines at the same time: IL-1, IL-33, and IL-36. And CAN10 has been designed to do that by binding to a specific part of IL1RAP, which is connecting to the receptors for these cytokines. And thereby the interactions are blocked, and the inflammatory signals are blocked. And we've seen very potent effects in several animal models of a large number of diseases. So, we're very confident that we have a potent drug which will generate significant interest. If we then go into the ages of Hidradenitis Suppurativa. It is a disease that is more common than most people think. It's affecting about 1% of the population in the Western world and starts with inflammation in hair follicles, which at that early stage can be treated with antibiotic paste or steroids. But once it gets more advanced, these inflamed hair follicles develop into something called draining tunnels, which are on the inside of the skin. And at that point in time, you will start systemic treatment with antibodies like Humira or recently with anti-IL-17. But the important message here is that even though these biological treatments are effective, they still manage to elicit a response from only about 50% of patients, leaving a significant medical need, especially in the later-stage populations. What has increased the interest for Cantargia here is two independent clinical trials, one from Boehringer Ingelheim using their IL-36 blocking antibody Spesolimab, which has shown efficacy especially on the draining tunnels, a very important part of the disease. The second drug, which has shown a great effect, is an IL-1 blocker, Lutikizumab from ABBVIE, which has shown effects on the more inflammatory part of the disease. And good data on what's called the high score of 50 and high score 75. And you can see the results to the right in this slide. So, the Spesolimab has a clear effect on the draining tunnels. And let's consider a composite score called IHS4. While Lutikizumab has demonstrated strong data on both the high score 50 and high score 75. So, to put this into context, IL1RAP is a co-receptor for both IL-1 and IL-36, and CAN10 blocks these. These both of these cytokines extremely potently. So we believe that we have a unique opportunity here to attack two different parts of the disease, both the inflammatory part as well as the draining tunnels. And thereby, we will be highly competitive with the other two drugs, which are based on the positive data and taken forward in clinical development for Hidradenitis Suppurativa by AbbVie and Boehringer Ingelheim. So, we are really excited to go forward here and to quickly comment on where we stand. So with CAN10, we have completed the single dose segment in healthy volunteers, and we have not observed any safety signals, which is obviously the purpose of this type of Phase 1 trial. But another very positive thing is that we have documented very clear dose-dependent receptor occupancy. So, the higher doses we treat with, the more CAN10 antibody will bind to disease-promoting immune cells, both monocytes as well as neutrophils. And as you can see down to the left, we clearly achieve full receptor occupancy, even at doses that are lower than those intended for upcoming clinical trials. And if you look to the right, we have taken whole blood from these individuals. We have stimulated the whole blood with IL-36 and then measured how responsive the cells are. And what you can see is that both day one and day eight, these cells are insensitive to IL-36 once they have been stimulated with or exposed to CAN10 in the patients. So again, a great result. And so we believe that we really squeezed out as much as we possibly could hope for in this phase part. And we're now doing multiple dosing in patients with psoriasis. And we expect to present data from those trials as they mature during the first half of next year and most likely sequentially. So when the cancer program. So, IL1RAP is also overexpressed on a large number of solid tumor types, which is really interesting. So you can say that somewhere between 70 to 90% of patients have some kind of overexpression of IL1RAP, and it's overexpressed both on the cancer cells and in the tumor stroma, typically on immune cells or fibroblasts. And this is of relevance to the work we're doing both in pancreatic cancer and lung cancer. And I will show you a little bit more of that in a second. So, as most of you know, we have positive data in pancreatic cancer. We have treated newly diagnosed patients with metastatic pancreatic cancer using a combination therapy. Typically, these patients would very quickly start therapy with a chemotherapy like Gemcitabine Abraxane. And we've added nadunolimab to this regimen and studied 73 patients across several European countries and approximately 15 different hospitals. So clearly a mix of patients. But we consistently see good results. And if you look to the left, you can see that the patients had a median survival of 13.2 months. This is somewhere 3 to 4 months longer than you would expect from gemcitabine. Abraxane. So, it is clearly associated with a survival benefit compared to what you would expect from historical controls in this trial. But what we also see, which you can observe on the right, is that when you measure the tumor size in these patients before and during therapy, quite a few of them experience a 50% or more reduction in tumor size. And this is a much better result than you would expect from chemotherapy alone. So the patients are clearly doing well when we add Nadunolimab to these patients. And what is also really interesting is that, since we have a targeted therapy, we have measured how much IL1RAP there is on the tumor cells. Then, we aimed to determine if there is a correlation between high and low IL1RAP levels. And there is a clear correlation. So, the patients who had the highest level of IL1RAP on their cancer cells are really the ones who are the strongest drivers of this efficacy signal. And this is really positive from two aspects. So the first one is that if our drug works, you probably should expect these patients to do better. But it's even better than that; if you have a high IL1RAP level, that's often correlated with very aggressive tumor mutations called KRAS mutations. And these patients have a worse prognosis than those with low IL1RAP. So in fact, you can say that patients with worse prognosis are the ones that are really benefiting the most in this trial, and this is clearly creating interest. And we will come back to how we are going to deliver on this. And then a second thing we discovered in this trial, which is further increasing the interest, is that chemotherapy also stimulates immune cells in nerve cells. And so, the chemotherapy, by stimulating these immune cells, will induce something called neuropathy. And what we have seen is that since Nadunolimab is an IL-1 blocker, we can observe that the higher the doses of Nadunolimab, the more pronounced the effect is on neuropathy. You can see that to the right. So the dose levels that we intend to use in the clinical trials are clearly delaying the onset of neuropathy. And it's also causing fewer patients to actually suffer from neuropathy. So this is really a great result. If you combine this in pancreatic cancer, you see that you both increase life expectancy and also reduce some of the serious side effects of chemotherapy. The result is clearly highly interesting in a very difficult-to-treat patient group. And then moving into non-small cell lung cancer. So what we see here is that again there is a subgroup of patients that are doing tremendously well. And that's what's called the non-squamous non-small cell lung cancer. And what? And that's a majority of the non-small cell lung cancer patients. So what we also see is that in this group of patients, we are doing tremendously well in patients that are second-line to immune therapy like the PD-1s. And one reason why we're getting such good effects in this patient population can be seen to the right. It may be difficult to see, but what we've done is stain the tumors from both patients who have not received immune therapy and those who have. And what we see is that once we stop responding to immune therapy, there has been an increase in IL1RAP positive immune cells in the tumor area, and that can most likely be linked to the unresponsiveness of the immune therapy. So our hypothesis is that once the drug gets into the tumor, it interacts with these immune cells, which then helps get our own immune system back on track. And this is also a result which is generating significant interest. But also, it's a highly competitive area. And for both, let's say, the pancreatic cancer opportunity as well as the non-small cell lung cancer opportunity. We have been out talking to various interested parties, so it could be specialist physicians, it can be investors, it can be pharma companies. And I think that the signal we're getting is that we have highly interesting data in both these indications, but we also live in a very competitive world. And to remain competitive, it's very clear we need to work with the patients that are most likely to respond. And to do that, we need robust diagnostic tests. And we have made initial progress in the development of these diagnostic tests. And we still have some validation work to be done. But we clearly believe that once they are ready, we will be in a much stronger position to go into late-stage development in both of these indications. So I think we will have very interesting discussions during 2025 now that we can deliver on this very important aspect of the program, and also the good safety and the reduction of neuropathy is driving the interest here as well. And as an investor, obviously you would like to see more data and various data being generated in additional cancers in the future, both triple negative breast cancer and leukemia. So I think this program is highly relevant. And we're strengthening now by having methods to select the patients most likely to respond. So again, to look at what type of milestones we have in front of us. So we have redesigned or are in the process of redesigning the pancreatic cancer trial. We will have new discussions with the FDA once we have advanced to work a little bit further on the diagnostic methods and to be ready to start. Though robust and solid clinical trials are expected during H2 next year in triple negative breast cancer. The randomized Phase 2 trial is ongoing. We expect the top-line data late in H1 this year, focusing on leukemia. We are very proud that we received the highly prestigious grant from the US Department of Defense to collaborate with MD Anderson Hospital at our cancer center in Houston. That trial is being prepared, and we hope to get the first patients in during this year. And CAN10, we presented lots of positive data during 2024, and I don't see any reason why we shouldn't continue to do that. So we will continue to present data on the MAD segment during H1, and we will conclude the MAD segment during H1 to be ready to start Phase 2 during H2 next year and again for the CAN10 program. We have also been out talking to Coles and to investors and pharma companies. The program is generating a lot of interest. It's still a bit early, but once we're getting closer to the start of phase two, I think we'll be in some very interesting discussions here. And we also have received very valuable feedback on where to go and how to position the drug in the best possible way. So by that, we're now coming into the rationale why we're doing this rights issue. We've had numerous discussions and I can say we hoped to be in a position to present some kind of partnership or other type of solutions. But all of these discussions have taken longer than expected or have ended up in various types of proposals which we do not think are in the interest of Cantargia shareholders. And in order to keep the momentum and continue to intensify the development. We're not pursuing this rights issue, and I believe we are doing so from a position of strength, supported by promising data from 300 cancer patients, with CAN10 being halfway through phase one and showing very interesting results, which influences our use of proceeds. Obviously, we have ongoing clinical trials and ongoing engagements. But one really, really important piece here is to develop this diagnostic method which has to be robust enough to measure expression of IL1RAP. So it can be used to select patients. And an interesting aspect here as well is that such an assay is not only important in pancreatic cancer, it may be adapted and may be a super important tool in non-small cell lung cancer. And as we advance CAN10, I'm sure these types of questions will arise as to whether we should pre-select patients with higher levels of IL1RAP, for instance, in skin or in various other types of tissues. And again, having this assay in place would be a highly competitive advantage. In CAN10, we are also undertaking a number of activities to strengthen ourselves ahead of Phase 2 and to be attractive for continued commercial discussions. And there are a number of aspects here. So we have toxicity studies. What we need to do to get more patient tissue to do more functional translational studies, for instance, in skin from patients with MS. . It's really going to be valuable ahead of the phase two trial. The product is also in a phase where we need to focus more on CMC development and production, which is obviously a significant part of this fundraising. And we're also planning to be in a strong position once we submit the application for an IND in the US, which is planned for the first half of next year. So by that, I would like to hand over to Patrick to go through more of the details around this rights issue. And then we're very happy to take questions.

Patrick
23:29 - 26:38

Thank you, Yaron, and good morning, everybody. So during the process that you alluded to, we have been in close contact with our major shareholders, and they have been supporting all the discussions and the plans that we've had. Um, in those discussions, we've also made sure that they are on board in securing the rights issue. And we are happy about that. So they are definitely supporting us here. The terms of the rights issue, as announced yesterday evening, are that the board proposes each shareholder holding two shares will be given the right to subscribe for one new share. This will lead to the issuing of approximately 92 million new shares at a price of 1.85 Swedish kronor per share, resulting in gross proceeds of approximately 170 million kronor. The. The rights issue is secured through subscription commitments from the major shareholders. As I alluded to in the beginning, the intention to subscribe from the board and management, along with a guarantee consortium, goes up to 120 million SEK, or approximately 70%. And I should say that this is a proposal made by the board, and it's subject to approval by an extraordinary general meeting that will be held on the 2nd of December. And obviously, in accordance with all the regulations. A prospectus needs to be filed and approved by the Swedish Financial Supervisory Authority. Today is the 6th of November. We'll announce our interim reports in a week's time. While we are doing that, the notice period for the extraordinary general meeting is ticking. It will be held on the 2nd of December. Shortly thereafter, we will disclose a prospectus on our webpage. And that will be the record date for the rights issue, with the subscription period starting shortly thereafter, targeted for December 6th and running through to December 20th, which means that we are currently estimating to announce the outcome of the rights issue shortly before Christmas. We received the proceeds around the end of the year or potentially early January. So with that, I conclude my overall presentation of the rights issue and the timelines, and I'll hand back for questions and answers.

Operator
26:44 - 27:14

If you wish to ask a question, please dial Pound Key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial Pound Key six on your telephone keypad. The next question comes from Sten Westerberg from Annalise Guiden. Please go ahead.

Sten Westerberg
27:16 - 27:18

Good morning. Can you hear me?

Yaron
27:19 - 27:20

Loud and clear.

Sten Westerberg
27:22 - 27:45

Thank you. Okay. I'm just curious to understand, uh, your historical method for measuring IL-1 expression. Uh, what has guided you so far in PDAC patients? How come this method will no longer serve in a later stage clinical trial?

Yaron
27:48 - 28:40

Yes, that's a technical question, but the original method was based on a polyclonal antibody set, which we validated. But for a commercial assay, we need a monoclonal antibody that can be produced reproducibly. And therefore, we have made a number of such monoclonal antibodies that work in paraffin tissue and provide the same results as the original polyclonal test. The polyclonal test cannot be produced in a reproducible manner and will not, let's say, be in accordance with the guidelines.

Sten Westerberg
28:44 - 29:07

Okay. Fair enough. So could you please expand a little bit on how this diagnostic test will be conducted in the future? Will you still be relying on histological biopsies, or will there be any blood or plasma tests available?

Yaron
29:10 - 30:01

Now, that's a great question. We will. So, this initial diagnostic test will certainly be developed for biopsies, which, for instance in the case of pancreatic cancer, is not too complicated as these patients are newly diagnosed from a biopsy. And also, in other forms of cancer, there obviously has to be an opportunity to take a biopsy. And then as we expand it further into skin diseases, it will be based on a skin biopsy. But I agree, having a blood test, which can be developed in parallel and become a second-generation test in the future, will be highly interesting.

Sten Westerberg
30:04 - 30:27

Okay. One final question, if I may. So, are you prioritizing any indication in this future pivotal study to come late in 2025, or are you still pondering on which indication you will look for?

Yaron
30:30 - 30:52

I think we are definitely at the most advanced stage in pancreatic cancer, where we have a pretty good idea of what the trial design and number of patients would look like. But, uh, we need to discuss that and get in agreement with the FDA before we disclose the numbers.

Unknown 1
30:52 - 30:56

But we need to discuss the number of patients and get an agreement with the FDA before we disclose the numbers. But the.

Sten Westerberg
30:57 - 30:59

Okay. Thank you. I'll get back in line.

Operator
31:05 - 31:26

As a reminder, if you wish to ask a question, please dial Pound Key five on your telephone keypad. There are no questions at this time, so I hand the conference back to the speakers for written questions and closing comments.

Unknown 2
31:28 - 31:47

Yes, there are a couple of questions coming from the web. And the first one is how is this new issue beneficial to existing shareholders if they want to buy additional shares by subscribing rather than buying them on the open market?

Yaron
31:52 - 32:30

Yeah. I don't know whether Patrick or I should. I can start, and then you can fill in, Patrick. But obviously, we're just at the starting point here with the rights. Let's say the period hasn't even started. So my hope is that we will see lots of interest in the company now, as this is a really great opportunity to get on board. This will allow us to observe how the share price responds under such pressure.

Patrick
32:34 - 32:54

Yes, I think it's difficult to predict what the share price is going to be. That's not for me and Huron to do, but I think we can only say that we are fully taking our shares or subscribing to our allotted shares in this issue. And so is the entire board and management.

Unknown 2
32:56 - 33:17

Thank you. Then a couple of questions relating to the PDAC study. Why? Why aren't you able to start that until the second half of 2025? And what are the costs? Um, related to that study? And will the proceeds from this rights issue be enough to start that study?

Yaron
33:19 - 34:16

So, the study design is still to be discussed and agreed upon with the FDA. All I can assure you is that, given we're now focusing on a subgroup of patients most likely to respond, the cost and the trial size will be smaller than if we targeted all comers. And, if we manage to garner interest for a Phase 3 trial, obviously it is not funded by this rights issue, but all the preparatory work and the discussions we have had make us very enthusiastic and also very optimistic that we can deliver something interesting in the future.

Unknown 2
34:18 - 34:32

Thank you. Regarding the biomarker route, what progress has been made and what are the future development plans? And are you partnering up with someone to accomplish this?

Yaron
34:34 - 35:40

Yeah. So, we have... So, first of all, I think it relates somewhat to the previous question. So, we had what could be called a type of research reagent to build the assay upon. And it was a really good reagent. But it's not fulfilling what you need to see in the commercial preparations. So we have made new monoclonal antibodies that seem to be highly specific and reproducible, also giving similar results as we did from the research-grade antibody. But we need to do additional validations in accordance with regulatory guidelines, which are quite labor-intensive work to be done. And we are working together with one of, let's say, the established diagnostic players in this field. But it takes time.

Unknown 2
35:40 - 35:50

Yeah. Are you considering developing your own ADCs targeting IL1RAP? Um, in the future?

Yaron
35:53 - 36:35

Yeah, absolutely. So, I think this is a great question and it's a great opportunity for Cantargia. So, Cantargia has been looking into making our own ADCs targeting IL1RAP. This is a really hot area and an area of interest, and it's something we'll probably be talking more about next year. But once we have more mature data, we also need to secure IP before presenting it. However, it is clearly a great opportunity and an opportunity which is also of interest for other parties.

Unknown 2
36:37 - 37:00

Thank you. And a couple of questions related to the partnering discussions. Why do you think they didn't conclude in a timely manner? And what do you think about the sort of rate of success in the future, continuing these discussions?

Yaron
37:02 - 38:14

So all I can say is that we had a number of discussions, both with specialist investors as well as pharmaceutical companies, and more specialized companies focused on certain disease areas. It is very difficult to say why things take longer time. It probably depends on what priorities the other parties may have and what type of opportunities they are looking for in parallel. So all I can say is that we have lots of interesting discussions ongoing. For some reason, we have not been able to deliver. But it's not that they are dead in any way. It just took longer time and didn't provide the offers we were looking for. And I think we have to, let's say, take our shareholders' interests into account and make sure that the company is well financed. And that's what we're doing right now.

Unknown 2
38:16 - 38:33

Thank you. And a couple of questions relating to costs. Are you still reviewing opportunities for further cost reductions? And is there any possibility to recover any costs from the pension corporation?

Yaron
38:37 - 39:31

So, obviously we try to be as cost-efficient as we possibly can. Uh, most of our costs are in. So, since we are a small, virtual company. Most of our costs are related to outsourcing of clinical trials and production. And other research agreements. But clearly, we're not investing in anything which we don't believe is value-adding to the company or necessary from a development perspective. Don't believe is value-adding to the company or necessary from a development perspective. And when it comes to pancreatic cancer, we did not invest any significant amount of money into that collaboration. As it ended before we started the clinical trial.

Unknown 2
39:33 - 39:34

Thank you.

Patrick
39:34 - 40:06

And maybe, maybe I can add. I mean, we are of course always looking into sources of non-dilutive funding. If we can apply for grants or run studies in a collaborative manner, such as. We are doing now with the M.D. Anderson Cancer Center in Houston, funded by, by or sponsored by Department of Defense. We are doing now with the M.D. Anderson Cancer Center in Houston, funded by, or sponsored by, the Department of Defense. So that’s not really cost cutting, if that’s the question, but it’s more about exploring alternative ways of funding important activities. And that's something we are always looking into.

Unknown 2
40:08 - 40:09

Thank you. And by that.

Yaron
40:09 - 40:36

And what I can add here is that there is also a large number of organizations, driven by such grants, that have approached us to conduct future clinical trials. We have nothing concrete set in stone, but there is also a great opportunity here to advance our programs.

Unknown 2
40:39 - 40:43

Thank you. And by that, we've covered all the written questions.

Operator
40:48 - 40:50

There are no more questions from the telecom.

Yaron
40:50 - 41:45

Yeah. So I would like to thank you for your attention. I can assure you that we will see lots of interesting events happening at Cantargia in 2025. Various interests from the outside world in what we're doing. We get lots of support from various experts in the medical fields who really think we're on the right track. I think the publication of the pancreatic cancer data in Clinical Cancer Research is clearly a recognition of that. I look forward to continuing this journey. We're sitting on some really interesting golden nuggets that we just need to make sure we continue to deliver on in the best possible way.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…